Janney Montgomery Scott’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.09M Buy
9,339
+2,836
+44% +$965K 0.01% 1065
2025
Q4
$2.59M Buy
6,503
+2,448
+60% +$1.08M 0.01% 1226
2025
Q3
$1.85M Buy
+4,055
New +$1.65M ﹤0.01% 1357
2025
Q1
Sell
-3,170
Closed -$746K 2669
2024
Q4
$746K Buy
3,170
+19
+0.6% +$5K ﹤0.01% 1746
2024
Q3
$867K Sell
3,151
-6
-0.2% -$1.56K ﹤0.01% 1601
2024
Q2
$767K Buy
3,157
+382
+14% +$60.3K ﹤0.01% 1600
2024
Q1
$415K Buy
2,775
+892
+47% +$149K ﹤0.01% 2120
2023
Q4
$360K Buy
+1,883
New +$321K ﹤0.01% 2114
2023
Q1
Sell
-1,051
Closed -$250K 2485
2022
Q4
$250K Buy
+1,051
New +$224K ﹤0.01% 2241
2022
Q3
Sell
-2,671
Closed -$380K 2492
2022
Q2
$380K Buy
+2,671
New +$379K ﹤0.01% 1763
2018
Q1
Sell
-1,577
Closed -$200K 1936
2017
Q4
$200K Buy
+1,577
New +$198K ﹤0.01% 1805
2016
Q1
Sell
-2,371
Closed -$223K 1267
2015
Q4
$223K Buy
+2,371
New +$220K 0.01% 1174
2015
Q3
Sell
-3,274
Closed -$392K 1388
2015
Q2
$392K Buy
3,274
+881
+37% +$105K 0.01% 1327
2015
Q1
$250K Buy
+2,393
New +$242K ﹤0.01% 1911

Other funds holding ALNY

Janney Montgomery Scott's ALNY Position: Q1 2026 in Review

Janney Montgomery Scott increased its Alnylam Pharmaceuticals (ALNY) stake by 44% in Q1 2026, buying an estimated $965K and bringing the position to 9,339 shares worth $3.09M. The position accounts for 0.01% of the portfolio, ranked #1065.

Janney Montgomery Scott first reported a position in ALNY in Q1 2015 and has held it in 14 quarters since. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Janney Montgomery Scott held 9,339 shares of Alnylam Pharmaceuticals worth $3.09M as of Q1 2026.
  • Janney Montgomery Scott bought 2,836 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $965K.
  • Alnylam Pharmaceuticals made up 0.01% of Janney Montgomery Scott's portfolio in Q1 2026, its #1065 holding.
  • Janney Montgomery Scott first reported a position in Alnylam Pharmaceuticals in Q1 2015 and has held it in 14 quarters since.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Janney Montgomery Scott's 13F filing for Q1 2026, filed 22 Apr 2026.